Press release
Gastroparesis Market Set to Witness Significant Growth by 2025-2034
Gastroparesis Market
Gastroparesis is a chronic gastrointestinal motility disorder characterized by delayed gastric emptying without mechanical obstruction. It leads to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal discomfort, often resulting in malnutrition and reduced quality of life.
The most common cause of gastroparesis is diabetes mellitus, particularly poorly controlled type 1 and type 2 diabetes. Other causes include post-surgical complications, neurological conditions, and idiopathic cases. With the global rise in diabetes and obesity, the prevalence of gastroparesis is increasing, creating higher demand for effective diagnostics and treatments.
Current treatment options include dietary modifications, prokinetic agents, antiemetics, gastric electrical stimulation, and surgery in severe cases. Advances in prokinetic drug development, improved diagnostic technologies, and personalized treatment approaches are reshaping the market outlook.
In 2024, the global Gastroparesis Market is valued at USD 4.6 billion and is projected to reach USD 9.3 billion by 2034, growing at a CAGR of 7.2% (2025-2034).
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71118
Market Overview
• Market Size 2024: USD 4.6 billion
• Forecast 2034: USD 9.3 billion
• CAGR (2025-2034): 7.2%
• Key Drivers: Rising diabetes prevalence, advances in diagnostic imaging and motility testing, pipeline progress in prokinetics, and growing awareness of gastrointestinal motility disorders.
• Key Challenges: Limited effective long-term therapies, treatment-related side effects, high recurrence rates, and underdiagnosis in emerging regions.
• Leading Players: Pfizer, Medtronic, Takeda, Evoke Pharma, Allergan (AbbVie), Johnson & Johnson (Ethicon), AbbVie, Theravance Biopharma, Ironwood Pharmaceuticals, AstraZeneca.
The market is expanding steadily, with opportunities in both pharmacological innovation and device-based interventions.
Segmentation Analysis
By Product
• Prokinetic agents (metoclopramide, domperidone, erythromycin)
• Antiemetics
• Gastric electrical stimulators
• Nutritional and dietary supplements
• Emerging therapies (ghrelin agonists, motilin agonists)
By Therapy
• Pharmacological therapy
• Device-based therapy (gastric stimulation)
• Nutritional and lifestyle management
• Combination therapy
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Specialty clinics
• Online pharmacies
By End-Use
• Hospitals
• Gastroenterology clinics
• Research institutes
• Homecare
By Application
• Diabetic gastroparesis
• Post-surgical gastroparesis
• Idiopathic gastroparesis
• Other causes (neurological, autoimmune)
Summary of Segmentation
The pharmacological therapy segment dominates, especially prokinetics, though device-based therapies like gastric electrical stimulators are gaining traction in refractory cases. The diabetic gastroparesis segment is the largest, reflecting the global diabetes epidemic.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71118/gastroparesis-market
Regional Analysis
• North America: Largest market share, supported by high diabetes prevalence, strong adoption of gastric stimulation devices, and advanced healthcare systems.
• Europe: Strong growth driven by high diagnosis rates, reimbursement frameworks, and adoption of prokinetics and surgical interventions.
• Asia-Pacific: Fastest-growing region (CAGR >8%), fueled by rising diabetes burden, increasing healthcare awareness, and improving access to advanced therapies.
• Middle East & Africa: Moderate growth, hindered by limited diagnostic infrastructure, though healthcare modernization is creating opportunities.
• Latin America: Brazil and Mexico lead growth, supported by rising obesity prevalence and increasing access to pharmacological therapies.
Regional Trends Summary
While North America and Europe dominate, Asia-Pacific is projected to record the fastest growth, reflecting rising diabetes rates, healthcare investments, and expanding clinical trial participation.
Market Dynamics
Key Growth Drivers
• Rising prevalence of diabetes and obesity worldwide.
• Expanding use of prokinetic therapies and gastric stimulation devices.
• Increasing awareness of gastrointestinal motility disorders.
• Strong clinical pipeline of novel prokinetic agents and ghrelin agonists.
Key Challenges
• Limited curative treatment options; current therapies are largely symptomatic.
• High recurrence rates and variable patient responses.
• Side effects of prokinetic drugs (neurological and cardiovascular risks).
• Underdiagnosis in developing countries due to lack of awareness and testing.
Latest Trends
• Development of ghrelin receptor agonists and next-generation motilin agonists.
• Use of AI-driven diagnostic imaging and motility testing.
• Expansion of gastric electrical stimulation for refractory cases.
• Integration of telemedicine and remote monitoring for long-term patient care.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71118
Competitive Landscape
Major Players
• Pfizer
• Medtronic
• Takeda
• Evoke Pharma
• Allergan (AbbVie)
• Johnson & Johnson (Ethicon)
• AbbVie
• Theravance Biopharma
• Ironwood Pharmaceuticals
• AstraZeneca
Competitive Insights
The Gastroparesis Market is innovation-driven, with Pfizer and Takeda leading in pharmacological therapies, while Medtronic dominates the gastric electrical stimulation segment. Startups such as Evoke Pharma are focusing on niche therapies (e.g., nasal metoclopramide). Strategic partnerships, R&D investments, and regulatory incentives for rare gastrointestinal disorders are driving competition.
Conclusion
The Gastroparesis Market is expanding significantly. From USD 4.6 billion in 2024 to USD 9.3 billion by 2034, the market is projected to grow at a CAGR of 7.2%, reflecting the growing diabetes burden, therapeutic innovation, and increasing awareness.
• Opportunities: Asia-Pacific expansion, next-generation prokinetics, and gastric electrical stimulation.
• Challenges: Limited curative solutions, side effects, and underdiagnosis.
• Key Takeaway: Companies that invest in innovative drug development, device-based therapies, and global access strategies will lead the gastroparesis market transformation in the coming decade.
This report is also available in the following languages : Japanese (胃不全麻痺市場), Korean (위장 마비 시장), Chinese (胃轻瘫市场), French (Marché de la gastroparésie), German (Gastroparese-Markt), and Italian (Mercato della gastroparesi), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71118
Our More Reports:
Barett Esophaguses Market
https://exactitudeconsultancy.com/reports/71106/barett-esophaguses-market
Ulcerative Colitis Market
https://exactitudeconsultancy.com/reports/71104/ulcerative-colitis-market
Chronic Spontaneous Urticaria (CSU) Patient Pool Market
https://exactitudeconsultancy.com/reports/71102/chronic-spontaneous-urticaria-csu-patient-pool-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastroparesis Market Set to Witness Significant Growth by 2025-2034 here
News-ID: 4158168 • Views: …
More Releases from Exactitude Consultancy
Irritable Bowel Syndrome (IBS) Market Growth, Trends, Consumer Demand and Key Op …
Introduction
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, altered bowel habits (constipation, diarrhea, or mixed), and recurrent discomfort. While not life-threatening, IBS significantly reduces quality of life and is often associated with psychological distress and comorbid conditions such as anxiety and depression.
The global IBS patient pool is increasing due to stressful lifestyles, dietary changes, rising prevalence of gastrointestinal disorders, and greater awareness leading…
Metabolic Dysfunction-Associated Steatohepatitis (MASH/NASH) Market Trends, Epid …
Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly referred to as Non-Alcoholic Steatohepatitis (NASH), is a progressive form of fatty liver disease characterized by fat accumulation, inflammation, hepatocyte injury, and varying degrees of fibrosis. It is closely linked to obesity, type 2 diabetes, metabolic syndrome, and cardiovascular risk factors.
MASH/NASH is a major global health burden, with prevalence rising due to the global obesity epidemic and sedentary lifestyles. If untreated, it can progress to…
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Insights and Future Outl …
Gastrointestinal Neuroendocrine Tumors (GI-NETs) Market Outlook 2024-2034: Advancing Diagnostics and Targeted Therapies to Drive Growth
Introduction
Gastrointestinal Neuroendocrine Tumors (GI-NETs) are rare malignancies that originate from neuroendocrine cells in the gastrointestinal tract, including the stomach, small intestine, colon. These tumors can be functioning (hormone-secreting) or non-functioning, often leading to late diagnoses. Symptoms vary widely and may include abdominal pain, diarrhea, flushing, and in advanced cases, metastasis to the liver.
Historically considered rare and…
Liver Cirrhosis Market Trends, Epidemiology and Future Outlook
Liver cirrhosis is a chronic, progressive liver disease characterized by scarring (fibrosis) and the gradual replacement of healthy liver tissue with scar tissue. This disrupts normal liver function, leading to portal hypertension, liver failure, and complications such as ascites, variceal bleeding, hepatic encephalopathy, and hepatocellular carcinoma (HCC).
The global burden of cirrhosis is rising due to the increasing prevalence of alcoholic liver disease, chronic hepatitis B and C, and non-alcoholic fatty…
More Releases for Gastroparesis
Top Trends Transforming the Gastroparesis Drugs Market Landscape in 2025: Develo …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Gastroparesis Drugs Industry Market Size Be by 2025?
The market size for drugs treating gastroparesis has significantly increased in the past few years. The progression is predicted to continue from $5.39 billion in 2024 to $5.73 billion in 2025, representing a compound annual growth rate (CAGR)…
Rising Healthcare Expenditure Fuels Growth In The Gastroparesis Market: Transfor …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Gastroparesis Industry Market Size Be by 2025?
In recent times, the gastroparesis market size has been witnessing a consistent growth. It is projected to advance from $6.84 billion in 2024 to $7.17 billion in 2025, registering a compound annual growth rate (CAGR) of 4.9%. Several factors…
Increasing Prevalence Of Diabetes Fuels Growth In The Gastroparesis Drugs Market …
The Gastroparesis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Gastroparesis Drugs Market?
The gastroparesis drugs market has grown strongly in recent years. It will rise from $5.39 billion in 2024 to $5.73 billion in 2025, at a…
Prominent Gastroparesis Drugs Market Trend for 2025: Development Of Innovative G …
What Are the Projected Growth and Market Size Trends for the Gastroparesis Drugs Market?
In recent times, the gastroparesis drugs market has experienced substantial growth. The market size is projected to expand from $5.39 billion in 2024 to $5.73 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. Various factors like the side effects associated with current treatments, research into gastrointestinal motility, clinical requirements, patient advocacy efforts and…
Gastroparesis Market Size | Segmentation, Outlook, Industry Report
The Gastroparesis Market was valued at US$ 4,338.61 million in 2019 and is projected to reach US$ 6,025.11 million by 2027; it is expected to grow at a CAGR of 4.3%during 2020-2027.
The growth of the market is mainly attributed to the increasing prevalence of diabetes and growing geriatric population. However, side effects of gastroparesis drugs obstruct the growth of the market.
Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00024714?utm_source=OpenPr&utm_medium=10640
Analysis of the Top Market…
Gastroparesis Market - Transforming lives through comprehensive gastroparesis tr …
Newark, New Castle, USA: The "Gastroparesis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gastroparesis Market: https://www.growthplusreports.com/report/gastroparesis-market/8691
This latest report researches the industry structure, sales, revenue, price and…
